Recent advances and impending challenges for the radiopharmaceutical sciences in oncology.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38821098.
- Also identified by DOI 10.1016/S1470-2045(24)00030-5 and PMC identifier 11340123.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This paper is the first of a Series on theranostics that summarises the current landscape of the radiopharmaceutical sciences as they pertain to oncology. In this Series paper, we describe exciting developments in radiochemistry and the production of radionuclides, the development and translation of theranostics, and the application of artificial intelligence to our field. These developments are catalysing growth in the use of radiopharmaceuticals to the benefit of patients worldwide. We also highlight some of the key issues to be addressed in the coming years to realise the full potential of radiopharmaceuticals to treat cancer.
Medical subject headings
- Radiopharmaceuticals
- Neoplasms